You are viewing the Novo Nordisk Virtual platform, provided to non-US health care professionals from around the world. By accessing this site and materials you accept this legal notice and expressly confirm your status as a healthcare professional.
This site is not country-specific and therefore may contain information which is not applicable to your country. Therefore, before prescribing any product, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics.
This site is not intended to provide medical advice and/or treatment guidance. Novo Nordisk accepts no liability for the accuracy, completeness or use of the information, and disclaims any liability to update the information contained on this site.
Glooko® allows patients to sync their NovoPen® 6 or NovoPen Echo® Plus device and analyse their insulin data alongside continuous glucose monitors (CGMs), popular blood glucose (BG) meters, and health and fitness devices. A variety of reports can be accessed via the Glooko® mobile app or Glooko® web app and securely shared with healthcare teams.
{{numberOfResults}} {{resultString}}
The Glooko® diabetes management system complies with regulatory requirements and is available in a number of European countries.
This is not a Novo Nordisk product but owned by Glooko®.
Glooko® affirms that it has met all the requirements of the Medical Device Directive (MDD 93/42/EEC) for CE marking (“Conformité Européenne”) in the European Economic Area (EEA).
NovoPen® 6 & NovoPen Echo® Plus Design Specification / Verification Report (Data on File).
Klonoff DC et al. JDiabetes SciTechnol. 2018;12(3):551-553.
Peter Adolfsson et al. Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. DIABETES TECHNOLOGY & THERAPEUTICS Volume 22, Number 10, 2020
Ashrafzadeh S, Hamdy O. Patient-driven diabetes care of the future in the technology era. Cell Metabolism. 2019; 29(3): 564-575.